Guided digital health intervention for depression in Lebanon: randomised trial.


Journal

Evidence-based mental health
ISSN: 1468-960X
Titre abrégé: Evid Based Ment Health
Pays: England
ID NLM: 100883413

Informations de publication

Date de publication:
12 2022
Historique:
received: 27 12 2021
accepted: 27 04 2022
pubmed: 17 5 2022
medline: 22 12 2022
entrez: 16 5 2022
Statut: ppublish

Résumé

Most people with mental disorders in communities exposed to adversity in low-income and middle-income countries (LMICs) do not receive effective care. Digital mental health interventions are scalable when digital access is adequate, and can be safely delivered during the COVID-19 pandemic. To examine the effects of a new WHO-guided digital mental health intervention, Step-by-Step, supported by a non-specialist helper in Lebanon, in the context of concurring economic, humanitarian and political crises, a large industrial disaster and the COVID-19 pandemic. We conducted a single-blind, two-arm pragmatic randomised trial, comparing guided Step-by-Step with enhanced care as usual (ECAU) among people suffering from depression and impaired functioning. Primary outcomes were depression (Patient Health Questionnaire 9 (PHQ-9)) and impaired functioning (WHO Disability Assessment Schedule-12 (WHODAS)) at post-treatment. 680 people with depression (PHQ-9>10) and impaired functioning (WHODAS>16) were randomised to Step-by-Step or ECAU. Intention-to-treat analyses showed effects on depression (standardised mean differences, SMD: 0.71; 95% CI: 0.45 to 0.97), impaired functioning (SMD: 0.43; 95% CI: 0.21 to 0.65), post-traumatic stress (SMD: 0.53; 95% CI: 0.27 to 0.79), anxiety (SMD: 0.74; 95% CI: 0.49 to 0.99), subjective well-being (SMD: 0.37; 95% CI: 0.12 to 0.62) and self-identified personal problems (SMD: 0.56; 95% CI 0.29 to 0.83). Significant effects on all outcomes were retained at 3-month follow-up. Guided digital mental health interventions can be effective in the treatment of depression in communities exposed to adversities in LMICs, although some uncertainty remains because of high attrition. Guided digital mental health interventions should be considered for implementation in LMICs. ClinicalTrials.gov NCT03720769.

Sections du résumé

BACKGROUND
Most people with mental disorders in communities exposed to adversity in low-income and middle-income countries (LMICs) do not receive effective care. Digital mental health interventions are scalable when digital access is adequate, and can be safely delivered during the COVID-19 pandemic.
OBJECTIVE
To examine the effects of a new WHO-guided digital mental health intervention, Step-by-Step, supported by a non-specialist helper in Lebanon, in the context of concurring economic, humanitarian and political crises, a large industrial disaster and the COVID-19 pandemic.
METHODS
We conducted a single-blind, two-arm pragmatic randomised trial, comparing guided Step-by-Step with enhanced care as usual (ECAU) among people suffering from depression and impaired functioning. Primary outcomes were depression (Patient Health Questionnaire 9 (PHQ-9)) and impaired functioning (WHO Disability Assessment Schedule-12 (WHODAS)) at post-treatment.
FINDINGS
680 people with depression (PHQ-9>10) and impaired functioning (WHODAS>16) were randomised to Step-by-Step or ECAU. Intention-to-treat analyses showed effects on depression (standardised mean differences, SMD: 0.71; 95% CI: 0.45 to 0.97), impaired functioning (SMD: 0.43; 95% CI: 0.21 to 0.65), post-traumatic stress (SMD: 0.53; 95% CI: 0.27 to 0.79), anxiety (SMD: 0.74; 95% CI: 0.49 to 0.99), subjective well-being (SMD: 0.37; 95% CI: 0.12 to 0.62) and self-identified personal problems (SMD: 0.56; 95% CI 0.29 to 0.83). Significant effects on all outcomes were retained at 3-month follow-up.
CONCLUSIONS
Guided digital mental health interventions can be effective in the treatment of depression in communities exposed to adversities in LMICs, although some uncertainty remains because of high attrition.
CLINICAL IMPLICATIONS
Guided digital mental health interventions should be considered for implementation in LMICs.
TRIAL REGISTRATION NUMBER
ClinicalTrials.gov NCT03720769.

Identifiants

pubmed: 35577536
pii: ebmental-2021-300416
doi: 10.1136/ebmental-2021-300416
pmc: PMC9811068
doi:

Banques de données

ClinicalTrials.gov
['NCT03720769']

Types de publication

Randomized Controlled Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e34-e40

Subventions

Organisme : World Health Organization
ID : 001
Pays : International

Informations de copyright

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Arch Intern Med. 2006 May 22;166(10):1092-7
pubmed: 16717171
Front Psychiatry. 2020 Feb 12;10:986
pubmed: 32116815
Lancet. 2020 Oct 31;396(10260):1380-1382
pubmed: 32919521
Int J Methods Psychiatr Res. 2003;12(2):85-91
pubmed: 12830302
World Psychiatry. 2018 Feb;17(1):90-101
pubmed: 29352530
Psychiatry Res. 2016 May 30;239:245-52
pubmed: 27031595
PLoS One. 2020 Jul 6;15(7):e0234349
pubmed: 32628678
World Psychiatry. 2019 Oct;18(3):325-336
pubmed: 31496095
JAMA Psychiatry. 2019 Jul 1;76(7):700-707
pubmed: 30994877
Int Psychogeriatr. 2020 Oct;32(10):1177-1180
pubmed: 32326986
BMC Public Health. 2021 Jan 26;21(1):217
pubmed: 33499834
PLoS One. 2014 Jul 16;9(7):e100674
pubmed: 25029507
Glob Ment Health (Camb). 2018 Nov 27;5:e39
pubmed: 30637112
Front Psychiatry. 2019 Jan 25;9:663
pubmed: 30740065
Lancet. 2006 Mar 25;367(9515):1000-6
pubmed: 16564362
Psychiatry Res. 2016 May 30;239:124-30
pubmed: 27137973
Br J Psychiatry. 2017 Feb;210(2):119-124
pubmed: 27908899
JMIR Res Protoc. 2021 Jan 28;10(1):e21585
pubmed: 33507158
Front Public Health. 2021 Jan 20;8:589264
pubmed: 33553090
Mhealth. 2018 Aug 13;4:34
pubmed: 30225240
Psychiatry Res. 2020 Dec;294:113520
pubmed: 33142145
Cochrane Database Syst Rev. 2018 Jul 05;7:CD011849
pubmed: 29975811
Eval Program Plann. 1979;2(3):197-207
pubmed: 10245370
Internet Interv. 2021 Mar 04;24:100380
pubmed: 33747798
J Gen Intern Med. 2001 Sep;16(9):606-13
pubmed: 11556941

Auteurs

Pim Cuijpers (P)

Department of Clinical, Neuro and Developmental Psychology, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands p.cuijpers@vu.nl.
Babeș-Bolyai University, International Institute for Psychotherapy, Cluj-Napoca, Romania.

Eva Heim (E)

Institute of Psychology, University of Lausanne, Lausanne, Switzerland.
Department of Psychology, University of Zurich, Zurich, Switzerland.

Jinane Abi Ramia (JA)

Department of Clinical, Neuro and Developmental Psychology, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
National Mental Health Programme, Ministry of Public Health of Lebanon, Beirut, Lebanon.

Sebastian Burchert (S)

Department of Education and Psychology, Freie Universität Berlin, Berlin, Germany.

Kenneth Carswell (K)

World Health Organization, Geneva, Switzerland.

Ilja Cornelisz (I)

Department of Educational, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.

Christine Knaevelsrud (C)

Department of Education and Psychology, Freie Universität Berlin, Berlin, Germany.

Philip Noun (P)

Department of Psychology, University of Zurich, Zurich, Switzerland.

Chris van Klaveren (C)

Department of Educational, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.

Edith Van't Hof (E)

Department of Mental Health and Substance Use, World Health Organization, Geneva, Switzerland.

Edwina Zoghbi (E)

World Health Organization, Geneva, Switzerland.

Mark van Ommeren (M)

World Health Organization, Geneva, Switzerland.

Rabih El Chammay (R)

National Mental Health Programme, Ministry of Public Health of Lebanon, Beirut, Lebanon.
Psychiatry Department, Saint Joseph University, Beirut, Lebanon.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH